Impact of Ascorbic Acid in the Prevention of Vancomycin Induced Nephrotoxicty

• Status: Recruiting
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: All

Summary

A Randomized controlled trial aiming to investigate whether ascorbic acid has a role in preventing vancomycin induced nephrotoxicity or not in critically ill patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Ascorbic Acid; Vancomycin

Criteria

Inclusion Criteria:

• Adults who are critically ill and with MRSA infection suspection.

Exclusion Criteria:

1. Pregnancy or breast feeding.

2. Known allergy to either vancomycin or ascorbic acid.

3. Base line serum creatinine ≥2mg/dl.

4. Patients receiving other nephrotoxic drug (e.g., aminoglycosides, amphotericin B, cisplatin or calcinurine inhibitors).

5. Anticepated administration of contrast medium within 7 days.

6. Patients suffering from some underlying diseases (e.g., cancer, HIV infection, systemic lupus erythematoses,or urinary tract stones).

7. Unlikelyhood of receiving the study medications for at least 72 hours